Event-driven primary disease-free survival ('DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ('PDAC”) is anticipated in 1H 2026Fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results